Daily Sabah logo

Politics
Diplomacy Legislation War On Terror EU Affairs Elections News Analysis
TÜRKİYE
Istanbul Education Investigations Minorities Expat Corner Diaspora
World
Mid-East Europe Americas Asia Pacific Africa Syrian Crisis Islamophobia
Business
Automotive Economy Energy Finance Tourism Tech Defense Transportation News Analysis
Lifestyle
Health Environment Travel Food Fashion Science Religion History Feature Expat Corner
Arts
Cinema Music Events Portrait Reviews Performing Arts
Sports
Football Basketball Motorsports Tennis
Opinion
Columns Op-Ed Reader's Corner Editorial
PHOTO GALLERY
JOBS ABOUT US RSS PRIVACY CONTACT US
© Turkuvaz Haberleşme ve Yayıncılık 2023

Daily Sabah logo

عربي
  • Politics
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • Elections
    • News Analysis
  • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Expat Corner
    • Diaspora
  • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • Islamophobia
  • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
  • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
  • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Reviews
    • Performing Arts
  • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
  • Gallery
  • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
  • TV
  • Life
  • Health
  • Environment
  • Travel
  • Food
  • Fashion
  • Science
  • Religion
  • History
  • Feature
  • Expat Corner

Pfizer begins mid to late trials for antiviral COVID-19 pill

by French Press Agency - AFP

WASHINGTON Sep 27, 2021 - 5:35 pm GMT+3
A sign for Pfizer pharmaceutical company is seen on a building in Cambridge, Massachusetts, U.S., March 18, 2017. (AFP Photo)
A sign for Pfizer pharmaceutical company is seen on a building in Cambridge, Massachusetts, U.S., March 18, 2017. (AFP Photo)
by French Press Agency - AFP Sep 27, 2021 5:35 pm
RECOMMENDED
An illustration shows the binary star system CPD-29 2176, located about 11,000 light-years from Earth. (Reuters Photo)

Not-so-super say astronomers: Milky Way supernova just a dud

space

Pfizer reported Monday that it had begun the Phase 2 and 3 of clinical trials to evaluate the effectiveness of an oral antiviral candidate pill that it hopes will be able to prevent COVID-19 infections in people exposed to the virus.

Several companies are working on so-called oral antivirals, which would mimic what the drug Tamiflu does for influenza and prevent the disease from progressing to severe.

"We believe that tackling the virus will require effective treatments for people who contract, or have been exposed to, the virus, complementing the impact that vaccines have had," said Mikael Dolsten, the company's chief scientific officer.

Pfizer started developing its drug, called PF-07321332, in March 2020 and is testing it in combination with ritonavir, a repurposed HIV medicine.

The clinical trial will enroll 2,660 adults who will take part at the first signs of COVID-19 infection or at first awareness of exposure.

They will be randomly assigned to receive either a combination of PF-07321332 and ritonavir, or a placebo twice a day for five or ten days.

The objective is to assess the safety and efficacy of the drugs being studied at preventing SARS-CoV-2 infection and symptomatic disease by day 14.

Other companies are also testing existing oral antivirals against COVID-19 – but Pfizer's is the first specifically designed against the coronavirus.

It is known as a "protease inhibitor" and has been shown in lab testing to jam up the virus' replication machinery.

If it works in real life, it will likely only be effective at the early stages of infection.

By the time COVID-19 progresses to severe disease, the virus has largely stopped replicating and patients suffer from an over-active immune response.

RECOMMENDED
An illustration shows the binary star system CPD-29 2176, located about 11,000 light-years from Earth. (Reuters Photo)

Not-so-super say astronomers: Milky Way supernova just a dud

space
  • shortlink copied
  • Last Update: Sep 27, 2021 7:08 pm
    RELATED TOPICS
    fight-against-terrorism DEUTSCHE-BANK US-LIBYA-RELATIONS
    KEYWORDS
    covid-19 treatment pfizer covid-19 vaccines treatment medicine
    The Daily Sabah Newsletter
    Keep up to date with what’s happening in Turkey, it’s region and the world.
    You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    A Turkish Airlines aircraft is seen as a snow plow cleans runway at Istanbul Airport, Istanbul, Türkiye, Jan. 24, 2022. (DHA Photo)

    Over 200 flights cancelled in Istanbul due to expected snowstorm

    snowstorm
    A shepherd's dog scratches itself in a rural area, Istanbul, Türkiye, Feb. 5, 2023. (Shutterstock Photo)

    Existence of wolves close to Istanbul seen as great blessing

    wild-animals

    Erdoğan slams opposition for making 'already done' promises

    turkish-elections

    Record-setting 'generational' Arctic blast grips NE US, Canada

    United-States
    No Image
    Jewelry, gems and so much more but all amber: Amberif 2022
    PHOTOGALLERY
    • POLITICS
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • News Analysis
    • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Diaspora
    • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • İslamophobia
    • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
    • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
    • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Performing Arts
    • Reviews
    • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
    • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
    • Photo gallery
    • Jobs
    • privacy
    • about us
    • contact us
    • RSS
    © Turkuvaz Haberleşme ve Yayıncılık 2021